Mometasona Furoato Alter Genéricos (Mometasone Furoate)

Mometasone furoate works by binding to glucocorticoid receptors inside nasal epithelial cells. The activated receptor complex alters gene transcription, suppressing the production of inflammatory cytokines, chemokines and adhesion molecules. This anti‑inflammatory action decreases immune‑cell infiltration and edema in the nasal mucosa, leading to rapid symptom improvement.

The appropriate dose of mometasone furoate nasal spray is determined by the prescribing clinician based on the patient’s age, severity of symptoms and specific indication. Typical regimens range from one to two sprays per nostril once daily, but the exact number of sprays, frequency and duration must follow the healthcare professional’s instructions.

Safety data for mometasone furoate in pregnancy are limited, and the drug should only be used if the potential benefit outweighs any possible risk to the fetus. During breastfeeding, only a small amount is expected to pass into milk; however, mothers should discuss use with their physician to assess safety for both infant and mother.

To order the product, submit an enquiry on the dedicated product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with minimal systemic absorption, offering once‑daily dosing for many patients. Compared with older agents such as beclomethasone or fluticasone, it often provides comparable or superior symptom control at lower doses, while maintaining a favorable safety profile. Choice of therapy should be individualized based on efficacy, tolerability, cost and patient preference.

The nasal spray should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the device upright, avoid freezing, and discard any remaining product after the indicated shelf‑life once opened, typically 30 days, as recommended by the manufacturer.

Mometasone furoate is delivered as a metered‑dose nasal spray. Before each use, gently shake the bottle, prime it by spraying a few times into the air if it is the first use, then tilt the head slightly forward. Insert the nozzle into one nostril, close the opposite nostril, and press the actuator to release the prescribed number of sprays. Breathe in gently through the nose and repeat for the other side if required.

Serious risks, although uncommon, include severe nosebleeds, perforation of the nasal septum, adrenal suppression with prolonged high‑dose therapy, opportunistic fungal infections of the nasal cavity, and systemic corticosteroid effects such as elevated intra‑ocular pressure or cataract formation. Patients should report persistent bleeding, visual changes or signs of infection to their healthcare provider promptly.

Mometasone furoate nasal spray is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with active untreated nasal infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid therapy is contraindicated. Consultation with a physician is essential before initiating treatment.